Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications

Jing He, Lei Huo, Junsheng Ma, Jun Zhao, Roland L. Bassett, Xiaoping Sun, Naoto T. Ueno, Bora Lim, Yun Gong

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Objectives Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in IBCs has been understudied. Methods In this study, tissue microarrays of 68 IBCs were immunostained with a PD-L1 antibody using an antibody clone (28-8) and detection system approved by the US Food and Drug Administration for selecting patients with non-small cell lung cancer and melanoma for anti-PD-L1 therapy. Results Positive PD-L1 expression was found in 25 (36.8%) of 68 samples but was not significantly associated with the clinicopathologic variables examined. Univariate analysis of overall survival (OS) revealed that worse OS was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative IBC. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS. Conclusions These findings indicate that PD-L1 inhibitors could potentially improve the clinical outcome of patients with PD-L1-positive IBC.

Original languageEnglish (US)
Pages (from-to)253-261
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume149
Issue number3
DOIs
StatePublished - Feb 17 2018
Externally publishedYes

Keywords

  • Breast
  • Immunohistochemistry
  • Inflammatory breast cancer
  • PD-L1
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications'. Together they form a unique fingerprint.

  • Cite this